Stryker Corp SYK
We take great care to ensure that the data presented and summarized in this overview for STRYKER CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SYK
View all-
Vanguard Group Inc Valley Forge, PA32.4MShares$12.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY26.8MShares$10.3 Billion0.21% of portfolio
-
Greenleaf Trust Kalamazoo, MI18.5MShares$7.14 Billion59.81% of portfolio
-
State Street Corp Boston, MA14.6MShares$5.62 Billion0.22% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.1MShares$4.26 Billion0.46% of portfolio
-
Jpmorgan Chase & CO New York, NY10.8MShares$4.17 Billion0.32% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$3.89 Billion0.65% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.05MShares$2.72 Billion0.55% of portfolio
-
Geode Capital Management, LLC Boston, MA6.91MShares$2.66 Billion0.21% of portfolio
-
Terry Smith Fundsmith LLP | London, X05.34MShares$2.06 Billion7.81% of portfolio
Latest Institutional Activity in SYK
Top Purchases
Top Sells
About SYK
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Insider Transactions at SYK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 18
2024
|
Glenn S Boehnlein VP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,979
-40.52%
|
$1,161,810
$390.08 P/Share
|
Nov 18
2024
|
Glenn S Boehnlein VP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+37.97%
|
$549,000
$122.51 P/Share
|
Nov 15
2024
|
Spencer S Stiles Group President |
SELL
Open market or private sale
|
Direct |
514
-1.01%
|
$200,974
$391.16 P/Share
|
Nov 14
2024
|
Spencer S Stiles Group President |
SELL
Bona fide gift
|
Direct |
129
-0.25%
|
-
|
Nov 07
2024
|
Kevin Lobo Chair and CEO |
SELL
Open market or private sale
|
Direct |
57,313
-13.99%
|
$21,091,184
$368.76 P/Share
|
Nov 07
2024
|
Kevin Lobo Chair and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
99,577
-38.76%
|
$36,743,913
$369.02 P/Share
|
Nov 07
2024
|
Kevin Lobo Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
156,890
+37.91%
|
$14,590,770
$93.06 P/Share
|
Nov 05
2024
|
Ronda E Stryker Director |
SELL
Open market or private sale
|
Indirect |
230,000
-0.89%
|
$84,180,000
$366.98 P/Share
|
Nov 05
2024
|
Yin C Becker VP, Chief Corp Affairs Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,189
-9.4%
|
$1,167,174
$366.9 P/Share
|
Nov 05
2024
|
Yin C Becker VP, Chief Corp Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,980
+12.8%
|
$478,080
$96.64 P/Share
|
Oct 01
2024
|
Spencer S Stiles Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-1.07%
|
$199,272
$361.26 P/Share
|
Oct 01
2024
|
James Andrew Pierce Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
641
-1.14%
|
$231,401
$361.26 P/Share
|
Sep 17
2024
|
M Kathryn Fink VP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
7,347
-4.82%
|
$2,689,002
$366.87 P/Share
|
Sep 16
2024
|
M Kathryn Fink VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,347
+29.7%
|
$896,334
$122.51 P/Share
|
Sep 13
2024
|
M Kathryn Fink VP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
2,121
-17.44%
|
$784,770
$370.0 P/Share
|
Aug 28
2024
|
William E Berry Jr VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,255
+19.84%
|
-
|
Aug 27
2024
|
Viju Menon Group President |
SELL
Open market or private sale
|
Direct |
600
-6.21%
|
$213,000
$355.0 P/Share
|
Aug 06
2024
|
Ronda E Stryker Director |
SELL
Open market or private sale
|
Indirect |
190,000
-0.55%
|
$60,990,000
$321.83 P/Share
|
Aug 06
2024
|
Ronda E Stryker Director |
SELL
Bona fide gift
|
Indirect |
14,925
-0.42%
|
-
|
Aug 06
2024
|
Robert S Fletcher VP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
633
+6.45%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 334K shares |
---|---|
Grant, award, or other acquisition | 90.7K shares |
Bona fide gift | 262 shares |
Payment of exercise price or tax liability | 245K shares |
---|---|
Open market or private sale | 835K shares |
Bona fide gift | 954K shares |